Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy

A method of lowering triglycerides in a subject on stable statin therapy having fasting triglycerides of about 200 mg/dl to less than 500 mg/dl and a fasting LDL-C level of about 40 mg/dl to about 100 mg/dl comprising, administering to the subject 2 g to about 4 g per day of a pharmaceutical composition comprising at least 96% pure ethyl-EPA for a period effective to lower fasting triglycerides in the subject.

A method of lowering triglycerides in a subject on stable statin therapy having fasting triglycerides of about 200 mg/dl to less than 500 mg/dl comprising, administering to the subject on statin therapy from 2 g to 4 g per day of a pharmaceutical composition comprising at least 96% pure ethyl-EPA for a period of about 1 to about 12 weeks thereby to lower fasting triglycerides in the subject by least 25% compared to a fasting triglyceride level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period, and wherein administration of the composition does not result in a statistically significant increase in fasting LDL-C compared to a fasting LDL-C level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period.